UNDERWRITING AGREEMENT among GLAXOSMITHKLINE CAPITAL INC. as Issuer GLAXOSMITHKLINE PLC as Guarantor and as Representatives of the Underwriters Dated as of [ ]Underwriting Agreement • March 4th, 2008 • Glaxosmithkline Capital PLC • Pharmaceutical preparations • New York
We have acted as special United States counsel to GlaxoSmithKline Capital Inc., a Delaware corporation (“GSK Capital Inc.”), and GlaxoSmithKline plc, a public limited company incorporated in England and Wales (the “Guarantor”), in connection with the offering from time to time, together or separately and in one or more series, pursuant to a registration statement on Form F-3 (No. 333-[ ]) of (i) guaranteed debt securities of GSK Capital Inc. (the “Debt Securities”) and (ii) guarantees of the Guarantor in respect of the Debt Securities (the “Guarantees” and, together with the Debt Securities, the “Securities”) to be issued under an indenture dated as of April 6, 2004 (the “Indenture”) among GSK Capital Inc., the Guarantor and Law Debenture Trust Company of New York (as successor to Citibank, N.A., pursuant to an Instrument of Resignation, Appointment and Acceptance dated December 27, 2007 among the Company, the Guarantor, Law Debenture Trust Company of New York and Citibank, N.A.), as t
INDENTURE among GLAXOSMITHKLINE PLC as Issuer and LAW DEBENTURE TRUST COMPANY OF NEW YORK as Trustee Dated as of March 4, 2008Indenture • March 4th, 2008 • Glaxosmithkline Capital PLC • Pharmaceutical preparations • New York
INDENTURE dated as of March 4, 2008, between GlaxoSmithKline plc, a public limited company incorporated under the laws of England and Wales (the “Company”), and Law Debenture Trust Company of New York, a trust company duly organized and existing under the laws of the State of New York, as trustee (the “Trustee”).
UNDERWRITING AGREEMENT between GLAXOSMITHKLINE PLC as Issuer and as Representatives of the Underwriters Dated as of [ ]Underwriting Agreement • March 4th, 2008 • Glaxosmithkline Capital PLC • Pharmaceutical preparations • New York
We have acted as special United States counsel to GlaxoSmithKline plc, a public limited company incorporated in England and Wales (the “Company”), in connection with the offering from time to time, together or separately and in one or more series, pursuant to a registration statement on Form F-3 (No. 333-[ ]) of (i) debt securities of the Company (the “Securities”) to be issued under an indenture dated as of March 4, 2008 (the “Indenture”) between the Company and Law Debenture Trust Company of New York, as trustee (the “Trustee”). Such registration statement, as amended as of its most recent effective date ([ ], 20[ ]), insofar as it relates to the Securities (as determined for purposes of Rule 430B(f)(2) under the Securities Act of 1933, as amended (the “Securities Act”)), but excluding the documents incorporated by reference therein, is herein called the “Registration Statement;” the related prospectus dated [ ], 20[ ], as first filed with the Securities and Exchange Commission (the
